Renaissance Capital logo

MBX Biosciences Priced, Nasdaq: MBX

Phase 2 biotech developing precision peptides for endocrine and metabolic diseases.

Industry: Health Care

Latest Trade: $23.75 0.00 (0.0%)

First Day Return: +47.8%

Return from IPO: +48.4%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEP™, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. We are advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities.
more less
IPO Data
IPO File Date 08/23/2024
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 10.2
Deal Size ($mm) $163
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 09/12/2024
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 10.2
Deal Size ($mm) $163
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
J.P. Morgan
Jefferies
more
Company Data
Headquarters Carmel, IN, United States
Founded 2018
Employees at IPO 36
Website www.mbxbio.com

MBX Biosciences (MBX) Performance